<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>医药笔记 | wechat-feeds</title><link>http://MzI4MzQyMjM0Ng.favicon.privacyhide.com/favicon.ico</link><description>乘之愈往，识之愈真。如将不尽，与古为新。</description><managingEditor> (hellodword)</managingEditor><pubDate>Fri, 04 Jun 2021 11:19:28 +0800</pubDate><image><url>http://MzI4MzQyMjM0Ng.favicon.privacyhide.com/favicon.ico</url><title>医药笔记 | wechat-feeds</title><link>http://MzI4MzQyMjM0Ng.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>岸迈生物研发PD-L1/TGFβ双抗</title><link>https://mp.weixin.qq.com/s/QynXlovSmsgudMJT4vTgMw</link><description></description><content:encoded><![CDATA[岸迈生物研发PD-L1/TGFβ双抗]]></content:encoded><pubDate>Fri, 04 Jun 2021 09:12:07 +0800</pubDate></item><item><title>恒瑞医药一季度营收69亿元，增幅25%</title><link>https://mp.weixin.qq.com/s/u1foiRLCFAIYKxJUmsXhww</link><description></description><content:encoded><![CDATA[恒瑞医药一季度营收69亿元，增幅25%]]></content:encoded><pubDate>Fri, 04 Jun 2021 09:12:07 +0800</pubDate></item><item><title>Nature：IgM新冠中和抗体</title><link>https://mp.weixin.qq.com/s/B845YHV0HGYzKoa4YJM4sQ</link><description></description><content:encoded><![CDATA[Nature：IgM新冠中和抗体]]></content:encoded><pubDate>Fri, 04 Jun 2021 09:12:07 +0800</pubDate></item><item><title>ASCO：新型肿瘤疫苗脱颖而出</title><link>https://mp.weixin.qq.com/s/2K_8CjTW4YfoeQwJDdMWDg</link><description></description><content:encoded><![CDATA[ASCO：新型肿瘤疫苗脱颖而出]]></content:encoded><pubDate>Thu, 03 Jun 2021 13:37:40 +0800</pubDate></item><item><title>ASCO：纳米药物NBTXR3逆转PD-1抵抗，联拓拥有中国权益</title><link>https://mp.weixin.qq.com/s/GfW7XcqLYjKMdM_fPTGPSQ</link><description></description><content:encoded><![CDATA[ASCO：纳米药物NBTXR3逆转PD-1抵抗，联拓拥有中国权益]]></content:encoded><pubDate>Thu, 03 Jun 2021 13:37:40 +0800</pubDate></item><item><title>岸迈生物申报BCMA/CD3双抗</title><link>https://mp.weixin.qq.com/s/oKYhNKQlx-ACOJ04fu850w</link><description></description><content:encoded><![CDATA[岸迈生物申报BCMA/CD3双抗]]></content:encoded><pubDate>Thu, 03 Jun 2021 13:37:40 +0800</pubDate></item><item><title>国内第7家：博际生物PD-L1/TGFβ双抗获FDA批准临床</title><link>https://mp.weixin.qq.com/s/7FUTog76iaLbGaynNvz8_w</link><description></description><content:encoded><![CDATA[国内第7家：博际生物PD-L1/TGFβ双抗获FDA批准临床]]></content:encoded><pubDate>Thu, 03 Jun 2021 13:37:40 +0800</pubDate></item><item><title>8.8亿美元：Genmab与Bolt合作开发3款肿瘤免疫ADC药物</title><link>https://mp.weixin.qq.com/s/QAhlsDlvulF3T1XnMJHy9A</link><description></description><content:encoded><![CDATA[8.8亿美元：Genmab与Bolt合作开发3款肿瘤免疫ADC药物]]></content:encoded><pubDate>Thu, 03 Jun 2021 13:37:40 +0800</pubDate></item><item><title>Morphosys 17亿美元收购Constellation</title><link>https://mp.weixin.qq.com/s/7oQ3jSbFVefHJmHdH6Ujnw</link><description></description><content:encoded><![CDATA[Morphosys 17亿美元收购Constellation]]></content:encoded><pubDate>Thu, 03 Jun 2021 13:37:40 +0800</pubDate></item><item><title>2021年最受期待10大新药，再鼎买了俩</title><link>https://mp.weixin.qq.com/s/pcdEG8MQrgTaKowkOln-ww</link><description></description><content:encoded><![CDATA[2021年最受期待10大新药，再鼎买了俩]]></content:encoded><pubDate>Wed, 02 Jun 2021 06:26:27 +0800</pubDate></item><item><title>License-in重磅药</title><link>https://mp.weixin.qq.com/s/1NA0pNkDJ-BqVLM4IfUwHg</link><description></description><content:encoded><![CDATA[License-in重磅药]]></content:encoded><pubDate>Wed, 02 Jun 2021 06:26:27 +0800</pubDate></item><item><title>科兴新冠疫苗获WHO批准EUA</title><link>https://mp.weixin.qq.com/s/Z4AC1VY567EBHmAKOQGSRA</link><description></description><content:encoded><![CDATA[科兴新冠疫苗获WHO批准EUA]]></content:encoded><pubDate>Wed, 02 Jun 2021 06:26:27 +0800</pubDate></item><item><title>12.5亿美元：安进引进协和发酵麒麟OX40抗体</title><link>https://mp.weixin.qq.com/s/7jQVtf-xZ_GsO_sZuARp-A</link><description></description><content:encoded><![CDATA[12.5亿美元：安进引进协和发酵麒麟OX40抗体]]></content:encoded><pubDate>Wed, 02 Jun 2021 06:26:27 +0800</pubDate></item><item><title>华博生物申报TIGIT抗体，国内第5家</title><link>https://mp.weixin.qq.com/s/LOGHH24txC7L8rqoPScWkA</link><description></description><content:encoded><![CDATA[华博生物申报TIGIT抗体，国内第5家]]></content:encoded><pubDate>Wed, 02 Jun 2021 06:26:27 +0800</pubDate></item><item><title>儿童节礼物：CDE网站开通“儿童用药专栏”</title><link>https://mp.weixin.qq.com/s/FPttgXLOEG7kJW8m5fY5JA</link><description></description><content:encoded><![CDATA[儿童节礼物：CDE网站开通“儿童用药专栏”]]></content:encoded><pubDate>Tue, 01 Jun 2021 10:48:42 +0800</pubDate></item><item><title>Ambrx技术全梳理</title><link>https://mp.weixin.qq.com/s/ZDHCULbVRZwPaQc8Lo6SJw</link><description></description><content:encoded><![CDATA[Ambrx技术全梳理]]></content:encoded><pubDate>Mon, 31 May 2021 13:17:07 +0800</pubDate></item><item><title>同润生物获CD3/CD19双抗授权</title><link>https://mp.weixin.qq.com/s/uRfdW-2DO3q6Gc2sZg9wAg</link><description></description><content:encoded><![CDATA[同润生物获CD3/CD19双抗授权]]></content:encoded><pubDate>Mon, 31 May 2021 13:17:07 +0800</pubDate></item><item><title>双靶向PROTAC</title><link>https://mp.weixin.qq.com/s/ZrRdjwBc5Z5XDLEuXaW5DA</link><description></description><content:encoded><![CDATA[双靶向PROTAC]]></content:encoded><pubDate>Sun, 30 May 2021 11:15:09 +0800</pubDate></item><item><title>填补新冠住院患者治疗空白：Humanigen递交GM-CSF抗体的EUA申请</title><link>https://mp.weixin.qq.com/s/hrSpWbDEjT5A88z4wofqCg</link><description></description><content:encoded><![CDATA[填补新冠住院患者治疗空白：Humanigen递交GM-CSF抗体的EUA申请]]></content:encoded><pubDate>Sat, 29 May 2021 07:03:30 +0800</pubDate></item><item><title>安进AMG 510获批上市，KRAS G12C占非小细胞肺癌13%</title><link>https://mp.weixin.qq.com/s/oSIF9r7Kf4Saw6yRDU_EGg</link><description></description><content:encoded><![CDATA[安进AMG 510获批上市，KRAS G12C占非小细胞肺癌13%]]></content:encoded><pubDate>Sat, 29 May 2021 07:03:30 +0800</pubDate></item></channel></rss>